首页> 外文期刊>Journal of Medicinal Chemistry >Identification of C-2 hydroxyethyl imidazopyrrolopyridines as potent JAK1 inhibitors with favorable physicochemical properties and high selectivity over JAK2
【24h】

Identification of C-2 hydroxyethyl imidazopyrrolopyridines as potent JAK1 inhibitors with favorable physicochemical properties and high selectivity over JAK2

机译:鉴定C-2羟乙基咪唑并吡咯并吡啶是强有效的JAK1抑制剂,具有良好的理化性质和比JAK2高的选择性

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

Herein we report on the structure-based discovery of a C-2 hydroxyethyl moiety which provided consistently high levels of selectivity for JAK1 over JAK2 to the imidazopyrrolopyridine series of JAK1 inhibitors. X-ray structures of a C-2 hydroxyethyl analogue in complex with both JAK1 and JAK2 revealed differential ligand/protein interactions between the two isoforms and offered an explanation for the observed selectivity. Analysis of historical data from related molecules was used to develop a set of physicochemical compound design parameters to impart desirable properties such as acceptable membrane permeability, potent whole blood activity, and a high degree of metabolic stability. This work culminated in the identification of a highly JAK1 selective compound (31) exhibiting favorable oral bioavailability across a range of preclinical species and robust efficacy in a rat CIA model.
机译:在本文中,我们报告了基于结构的C-2羟乙基部分的发现,该发现为JAK1抑制剂对JAK1的咪唑并吡咯并吡啶系列提供了持续较高的选择性。与JAK1和JAK2配合的C-2羟乙基类似物的X射线结构揭示了两种同工型之间的配体/蛋白质相互作用不同,并为观察到的选择性提供了解释。来自相关分子的历史数据分析被用于开发一组理化化合物设计参数,以赋予所需的特性,例如可接受的膜通透性,有效的全血活性和高度的代谢稳定性。这项工作最终确定了高度JAK1选择性化合物(31),该化合物在一系列临床前物种中均表现出良好的口服生物利用度,并在大鼠CIA模型中具有强大的功效。

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号